Contrasting of Eton Pharmaceuticals Inc. (ETON) and Verastem Inc. (NASDAQ:VSTM)

Eton Pharmaceuticals Inc. (NASDAQ:ETON) and Verastem Inc. (NASDAQ:VSTM) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eton Pharmaceuticals Inc. 7 222.04 N/A -2.36 0.00
Verastem Inc. 2 4.62 N/A -1.26 0.00

Table 1 demonstrates Eton Pharmaceuticals Inc. and Verastem Inc.’s gross revenue, earnings per share and valuation.


Table 2 demonstrates the return on assets, return on equity and net margins of Eton Pharmaceuticals Inc. and Verastem Inc.

Net Margins Return on Equity Return on Assets
Eton Pharmaceuticals Inc. 0.00% 0% -238.9%
Verastem Inc. 0.00% -80% -40.8%


Eton Pharmaceuticals Inc. has a Current Ratio of 5.9 and a Quick Ratio of 5.9. Competitively, Verastem Inc.’s Current Ratio is 7.6 and has 7.6 Quick Ratio. Verastem Inc.’s better ability to pay short and long-term obligations than Eton Pharmaceuticals Inc.

Analyst Recommendations

Ratings and Recommendations for Eton Pharmaceuticals Inc. and Verastem Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Eton Pharmaceuticals Inc. 0 0 0 0.00
Verastem Inc. 0 0 3 3.00

Meanwhile, Verastem Inc.’s consensus price target is $7, while its potential upside is 422.39%.

Insider and Institutional Ownership

Institutional investors held 9.2% of Eton Pharmaceuticals Inc. shares and 47% of Verastem Inc. shares. Insiders held roughly 5.8% of Eton Pharmaceuticals Inc.’s shares. Comparatively, Verastem Inc. has 0.4% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Eton Pharmaceuticals Inc. -2.56% -18.8% -17.7% -1.77% 0% -0.49%
Verastem Inc. 13.64% 6.38% -28.23% -53.42% -80.05% -55.36%

For the past year Eton Pharmaceuticals Inc. was less bearish than Verastem Inc.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The companyÂ’s defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. The companyÂ’s duvelisib is in Phase 3 randomized and two-arm trial for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with refractory indolent non-Hodgkin lymphoma. The company has license agreement with Infinity Pharmaceuticals, Inc.; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.